Rare inherited blood disorders
Pyruvate kinase deficiency: symptoms, diagnosis and treatment
Pyruvate kinase deficiency (PKD) is a rare inherited condition in which red blood cells lack a key enzyme and are destroyed too early, causing haemolytic anaemia. It ranges from mild disease that may go unnoticed to severe anaemia needing transfusions. This guide explains the symptoms, how it is diagnosed, and the treatments described by UK and European sources. UK patient-facing information is limited, so some sources are professional or European.
Last checked: 2026-10-10
Key facts
At a glance.
-
Inherited enzyme problem
The European Medicines Agency describes it as an inherited disease affecting red blood cells, caused by mutations in the gene for the enzyme pyruvate kinase, leading to early breakdown of these cells (haemolytic anaemia).
-
Wide range of severity
Patient.info’s professional article says the anaemia may vary from a very mild, fully compensated form to life-threatening neonatal anaemia requiring exchange transfusion.
-
Autosomal recessive
Patient.info says the family history is consistent with autosomal recessive inheritance and that more than 150 different causative mutations have been identified.
-
Typical symptoms
The EMA lists very pale skin, jaundice, tiredness, shortness of breath, an enlarged spleen and heart problems, and notes that anaemia can worsen during pregnancy or a viral infection.
-
Supportive care is the base
Management is usually supportive, with red cell transfusion if haemoglobin falls significantly; some transfusion-dependent people have benefited from splenectomy.
-
A newer medicine exists
The EMA says mitapivat (Pyrukynd) has been authorised in the EU since 9 November 2022; ask a specialist about availability in the UK.
What pyruvate kinase deficiency is
Red blood cells carry oxygen around the body. To do their job they need energy, and pyruvate kinase is an enzyme in the pathway that produces it. The Patient.info professional article explains that in PKD the red cell’s energy requirements outstrip its ability to generate ATP, which damages the cell membrane irreversibly, so the damaged cell is destroyed prematurely by the spleen and liver.
The result is haemolytic anaemia, in which red cells are broken down faster than the body can replace them. The European Medicines Agency describes PKD as an inherited disease that is long-term and debilitating because of its symptoms and the periodic blood transfusions that some people need. Patient.info says it is the most common enzyme abnormality of this energy pathway.
Symptoms and complications
Symptoms depend on severity. The EMA lists very pale skin, yellowing of the eyes and skin (jaundice), tiredness, shortness of breath, an enlarged spleen (splenomegaly) and heart problems. Patient.info adds that milder forms may be unnoticed until some physiological stress is experienced, such as pregnancy or a viral infection, that children may have signs of anaemia, growth delay and failure to thrive, and that most cases are found in childhood although mildly affected people may not be detected until late adulthood.
Gallstones are a recognised complication, which Patient.info says occasionally present in childhood but usually after the first decade, and adults may have chronic leg ulcers. Other complications listed are bacterial sepsis after splenectomy and iron overload from many transfusions. Anaemia can worsen during pregnancy or a viral infection, according to the EMA, and can be life threatening.
How it is diagnosed
Diagnosis begins with a blood count and film that show anaemia and signs of accelerated red cell production, such as a raised reticulocyte count and nucleated red blood cells. Patient.info says the blood film features, a reduced red cell lifespan and a raised bilirubin reflect the haemolysis, and that tests for other haemolytic conditions, such as haemoglobin electrophoresis and red cell fragility, are normal.
The precise diagnosis depends on detecting the deficient enzyme, and Patient.info says measuring intermediate products in the pathway helps to confirm it. DNA analysis is limited because of the large number of possible mutations and is of greater value when the mutation is already known. A GP would normally refer to haematology.
Treatment
Patient.info says management is usually supportive in mild to moderate cases. The EMA adds that at the time its orphan designation was granted there were no satisfactory authorised treatments and that patients received periodic red cell transfusions and, in some, allogeneic stem-cell transplantation.
| Approach | What it involves | Points from the sources |
|---|---|---|
| Supportive care | Treating the anaemia and its complications | Usual for mild to moderate disease |
| Red cell transfusion | Given if haemoglobin falls significantly, or periodically in more severe disease | Iron overload can follow many transfusions |
| Splenectomy | Removal of the spleen in some transfusion-dependent people | May reduce anaemia but haemolysis continues; risk of sepsis afterwards |
| Mitapivat (Pyrukynd) | A medicine thought to stabilise the defective enzyme | EMA: authorised in the EU since 9 November 2022 |
| Stem-cell or bone marrow transplant | Replacing the bone marrow from a matched donor | Has been successful in some people; used in selected severe cases |
Inheritance and family planning
Patient.info says inheritance is autosomal recessive, meaning a child inherits one altered gene from each parent, who are usually carriers without symptoms, and that most affected people are compound heterozygotes with two different mutations. It notes that prenatal enzyme testing is not useful because of the large amount of fetal blood needed and a high rate of false negatives, and that DNA testing is most useful when the family mutation is known.
Pregnancy outcomes are generally good according to the same article, despite sometimes severe falls in haemoglobin during pregnancy, so pregnancy planning should involve haematology and obstetric teams. Genetic counselling through a clinical genetics service can explain the chance of a child being affected.
When to get help
See a GP if you have persistent tiredness, pallor, jaundice or breathlessness. Seek urgent medical advice through NHS 111 or A&E if you have a high temperature, particularly after splenectomy, severe breathlessness, chest pain, a very rapid heartbeat or marked yellowing, because anaemia can worsen during a viral infection and sepsis after splenectomy is a recognised risk. Call 999 if you are seriously unwell.
Living with PKD
Most of the literature the sources draw on is aimed at clinicians, and patient-facing UK information is limited. The sources identify pregnancy and viral infections as times when anaemia can worsen, and gallstones, iron overload after many transfusions and infection after splenectomy as complications to be aware of. Ask your haematologist what monitoring you need and which team coordinates your care.
Frequently asked
Questions people ask.
Quick, plain-English answers to the questions we hear most.
-
What causes pyruvate kinase deficiency?
Mutations in the gene that makes the red cell enzyme pyruvate kinase. The EMA says this leads to reduced lifespan and early breakdown of red cells (haemolytic anaemia).
-
How is it inherited?
Patient.info says inheritance is autosomal recessive; both parents carry an altered gene, usually without symptoms. More than 150 different mutations have been identified.
-
Is it the same as G6PD deficiency?
No. Both are inherited red cell enzyme conditions that can cause haemolytic anaemia, but they involve different enzymes, and Patient.info covers G6PD deficiency in a separate article.
-
Does everyone with PKD need transfusions?
No. Severity varies from mild, fully compensated anaemia to severe disease. Patient.info says management is usually supportive in mild to moderate cases.
-
What does splenectomy do?
Patient.info says it may reduce anaemia in some transfusion-dependent people but does not improve mild anaemia and haemolysis continues. Infection risk afterwards needs managing.
-
Is there a drug for PKD?
Mitapivat (Pyrukynd) is described by the EMA as authorised in the EU since November 2022 and thought to work by stabilising the defective enzyme. Ask your specialist about UK availability and eligibility.
-
Can I have a healthy pregnancy?
Patient.info says pregnancy outcomes are generally good despite sometimes severe declines in haemoglobin, so close haematology and obstetric care is important.
-
Why am I getting gallstones?
Breakdown of red cells produces bilirubin, which can form stones. Patient.info lists gallstones and biliary obstruction as complications.
-
How rare is it?
Patient.info quotes an estimated prevalence of 51 per million from gene frequency studies, with 3.3 per million observed in one northern England region. The EMA says fewer than 0.5 in 10,000 people in the EU were affected.
Where this comes from
Sources and checking.
This guide is for information, not medical advice.
Your GP or consultant knows your history and can tell you which parts apply to you. If your symptoms are severe, rapidly worsening, or come with red-flag features, seek urgent medical care. Figures and availability change, so treat them as a guide and confirm with the provider.
Published 2026-10-10, next review 2027-10-10.
-
Patient.info (Professional Reference, UK): Pyruvate kinase deficiency, last updated August 2011 and not recently reviewed, https://patient.info/doctor/pyruvate-kinase-deficiency , retrieved October 2026
-
European Medicines Agency: EU/3/20/2270 orphan designation for treatment of pyruvate kinase deficiency (non-UK regulator), https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2270 , retrieved October 2026
Related guides
Keep reading.
-
Haemolytic anaemia
Early destruction of red blood cells.
Read guide -
G6PD deficiency
Another inherited red cell enzyme condition.
Read guide -
Hereditary spherocytosis
An inherited red cell membrane condition.
Read guide -
Splenectomy
Removal of the spleen and its consequences.
Read guide -
Blood film explained
What a blood film shows in haemolysis.
Read guide